Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies (Q37863518)

24 August 2017

1 reference

title

Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies (English)

1 reference

24 August 2017

4

John Greenwood

0 references

author name string

Yeranddy A Alpizar

1

1 reference

24 August 2017

Benjamin Chain

2

1 reference

24 August 2017

Mary K Collins

3

1 reference

24 August 2017

David Katz

5

1 reference

24 August 2017

Hans J Stauss

6

1 reference

24 August 2017

N Avrion Mitchison

7

1 reference

24 August 2017

9 April 2011

1 reference

Cancer Immunology, Immunotherapy

24 August 2017

1 reference

24 August 2017

60

1 reference

24 August 2017

8

1 reference

24 August 2017

1127-1135

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-0985-7

24 August 2017

0 references

cites work

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Adaptive immunity maintains occult cancer in an equilibrium state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Improving the efficacy of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Testing the theory of immune selection in cancers that break the rules of transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Human T cell responses against melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Immune selective pressure and HLA class I antigen defects in malignant lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

The HLA system: structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Different regulation of MHC class I antigen processing components in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Prospects for the use of NK cells in immunotherapy of human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Can NK cells be a therapeutic target in human cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Amplification of immune responses against a DNA-delivered idiotypic lymphoma antigen by fusion to the B subunit of E. coli heat labile toxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

A decade of progress in lymphoma: advances and continuing challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

An essential developmental checkpoint for production of the T cell lineage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Mechanisms of resistance to HER family targeting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Plasma membrane proteomics and its application in clinical cancer biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Identification of prostate cancer antigens by automated high-throughput filter immunoscreening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Development trends for human monoclonal antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Oncolytic viruses: time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Epigenetic aberrations and therapeutic implications in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Immunity to stemness genes in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

The human T cell response to melanoma antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Immune responses in mice to tumour challenge after immunization with newcastle disease virus-infected or X-irradiated tumour cells or cell fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Regulatory T cells in immune surveillance and treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

DNA vaccines against cancer come of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Adoptive cell therapy: genetic modification to redirect effector cell specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Dendritic cell vaccine strategies for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-0985-7

10.1007/S00262-011-0985-7

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference